Analysis of liver metastasis in colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study focuses on the integrative analysis of liver metastasis in colorectal cancer (CRC) by examining the proteomes of paired normal colorectal tissues and CRC tissues with or without liver metastasis. The methodology includes sequencing transcriptomes, whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets of normal colorectal tissue, primary CRC, and its matched liver metastasis. Additionally, the study will analyze genomic data from CRC previously characterized by The Cancer Genome Atlas (TCGA) to conduct comprehensive proteogenomic analyses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≤ 75 years with histologically proven CRC
* No severe major organ dysfunction
* WHO performance status of 0 or 1
* No prior cancer chemotherapy

Exclusion Criteria:

* Age ≥ 76
* Severe major organ dysfunction
* World Health Organization (WHO) performance status of \>1
* Prior cancer chemotherapy

Where it's running

• Ganzhou City People's Hospital
  Ganzhou, Jiangxi, China Recruiting
• Shanghai Tenth People's Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Principal investigator: Da Fu, Ph.D. — the Shanghai Tenth People's Hospital
• Study coordinator: Da Fu, Ph.D.
• Email: shsyiec@126.com
• Phone: 021-66301604

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Luvometinib plus Anlotinib in KRAS-mutated NSCLC

  This study tests whether the combination of luvometinib and anlotinib helps people with KRAS-mutated metastatic non-small cell lung cancer who have tried prior treatments.

  Recruiting Phase 2 Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Shanghai, Shanghai Municipality · NCT07562581

• Gefitinib, trametinib, disulfiram, and sunitinib added to standard chemotherapy for metastatic osteosarcoma

  This study tests whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy helps people with newly diagnosed metastatic osteosarcoma.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07477457

• Outcomes for Oligometastatic and Oligorecurrent Cervical Cancer

  This registry will see if adding local treatments such as radiation or surgery to standard systemic therapy helps people with oligo‑metastatic or oligo‑recurrent cervical cancer live longer or avoid progression.

  Recruiting Tata Memorial Hospital · Mumbai, Maharashtra · NCT07400809

• Fast detection of cancer in sentinel lymph nodes using a new NIR-II fluorescent probe.

  This test applies a new near-infrared (NIR-II) fluorescent probe to freshly removed sentinel lymph nodes to quickly tell adults with breast cancer whether the cancer has spread there.

  Recruiting Yunnan Cancer Hospital · Kunming, Yunnan · NCT07154563

• Two-point versus four-point cervical methylene blue injections for sentinel lymph node mapping in stage I endometrial cancer

  This test checks whether using four cervical methylene blue injections instead of the usual two helps surgeons find sentinel lymph nodes in people with newly diagnosed stage I endometrial cancer who are having surgery.

  Recruiting at 2 sites Dokuz Eylul University · Ankara and 1 other locations · NCT07040657

• Real-world look at SKB264 in HER2-negative breast cancer that has come back or spread

  This real-world study tests sacituzumab tirumotecan (SKB264) alone or with others in adults with recurrent or metastatic HER2-negative breast cancer.

  Recruiting at 12 sites Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hefei, Anhui and 18 other locations · NCT06993506

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.